high
throughput
accur
assay
antisarscov
igg
detect
need
largescal
epidemiolog
studi
evalu
commerci
recombin
nucleocapsid
proteinbas
microtitr
plate
enzym
immunoassay
elisar
tm
describ
result
sera
sar
patient
sera
nonsar
control
show
assay
high
level
sensit
late
serum
sampl
specif
perform
setup
assay
fulfil
requir
screen
test
largescal
studi
vast
major
sar
patient
develop
antibodi
nucleocapsid
protein
patient
high
level
antinucleocapsid
antibodi
appear
earli
cours
ill
contrast
minor
patient
never
develop
antibodi
implic
differ
antibodi
respons
nucleocapsid
protein
deserv
investig
march
global
alert
rais
newli
recogn
infecti
diseas
sever
acut
respiratori
syndrom
sar
later
identifi
caus
sarsassoci
coronaviru
sarscov
observ
previous
human
fouchier
et
al
ksiazek
et
al
kuiken
et
al
peiri
et
al
novel
coronaviru
clinic
epidemiolog
characterist
distinct
known
human
coronavirus
lee
et
al
peiri
et
al
rainer
although
research
sarscov
progress
rapidli
substanti
bodi
knowledg
still
miss
end
high
throughput
assay
largescal
seroepidemiolog
studi
need
recent
studi
shown
nucleocapsid
protein
react
larg
proport
sera
collect
sar
patient
sensit
upto
report
enzym
immunoassay
base
nucleocapsid
protein
wang
et
al
timani
et
al
howev
specif
nucleocapsid
proteinbas
assay
still
unknown
report
evalu
commerci
avail
assay
elisar
tm
iggen
hong
kong
detect
antisar
covimmunoglobulin
ig
g
human
serum
sampl
enzym
immunoassay
eia
elisar
tm
iggen
base
escherichia
coli
express
bacteri
glutathion
stransferas
gst
fuse
recombin
nucleocapsid
protein
sarscov
recombin
protein
select
base
observ
previou
studi
leung
et
al
assay
procedur
perform
instruct
manufactur
protocol
briefli
serum
sampl
ad
antigenco
well
microtitr
plate
incub
step
well
wash
follow
addit
antihuman
igg
antibodi
conjug
horseradish
peroxidas
second
wash
tmb
ad
substrat
color
develop
optic
densiti
od
measur
nm
result
interpret
accord
manufactur
criteria
specimen
od
read
consid
neg
wherea
specimen
od
read
consid
posit
cutoff
valu
accord
manufactur
recommend
serum
sampl
also
test
inhous
indirect
immunofluoresc
assay
ifa
describ
previous
assay
base
acetonefix
vero
cell
infect
sarscov
strain
genbank
access
method
use
refer
studi
shown
highli
sensit
specif
total
sar
patient
age
mean
sd
year
femal
male
recruit
studi
patient
fulfil
modifi
criteria
defin
world
health
organ
probabl
case
sar
world
health
organ
patient
either
seroconvers
fourfold
rise
antisarscov
igg
antibodi
level
detect
inhous
ifa
three
patient
die
requir
intens
care
eventu
recov
other
develop
milder
degre
pneumonia
requir
intub
intens
care
total
serum
sampl
collect
day
median
interquartil
rang
onset
fever
purpos
studi
analysi
sampl
refer
late
sampl
anoth
sampl
collect
day
median
interquartil
rang
onset
fever
sampl
refer
earli
sampl
total
control
serum
sampl
includ
studi
medic
student
age
mean
sd
year
compris
femal
male
sampl
collect
prevaricella
vaccin
examin
two
hundr
fifti
serum
sampl
collect
patient
admit
princ
wale
hospit
fever
pneumonia
serv
nonsar
pneumonia
control
compris
serum
sampl
adult
age
mean
sd
year
femal
male
elderli
age
mean
sd
year
femal
male
pediatr
age
mean
sd
year
femal
male
serum
sampl
obtain
sar
group
test
posit
antisarscov
igg
elisar
tm
kit
iggen
tabl
except
one
eiaposit
specimen
also
test
posit
ifa
ifaneg
specimen
collect
day
onset
fever
later
serum
collect
patient
posit
eia
ifa
eianeg
specimen
test
posit
ifa
major
eianeg
ifaposit
sampl
high
ifa
titr
detect
rang
correl
od
read
ifa
titr
sampl
collect
sar
patient
shown
figur
overal
posit
associ
eia
od
read
ifa
titr
observ
p
kruskalw
test
howev
one
ifaneg
sampl
high
eia
od
read
sampl
high
ifa
titr
show
low
level
od
read
correl
time
specimen
collect
elisar
tm
kit
iggen
show
sensit
late
specimen
day
earli
specimen
day
respect
tabl
correspond
sensit
ifa
respect
od
read
sar
nonsar
sampl
posit
antinucleocapsid
protein
igg
eia
shown
figur
major
trueposit
sampl
taken
sar
patient
od
read
twice
cutoff
wherea
falseposit
sampl
taken
nonsar
group
low
level
od
read
cutoff
altogeth
sampl
nonsar
control
group
posit
antisarscov
igg
elisar
tm
kit
tabl
sampl
subsequ
test
neg
ifa
suggest
nonspecif
eia
od
read
eia
falseposit
specimen
shown
figur
overal
specif
elisar
tm
kit
iggen
rang
without
signific
variat
among
differ
group
control
p
exact
test
seropreval
studi
play
import
role
reveal
epidemiolog
infecti
diseas
highli
sensit
specif
assay
high
throughput
capac
requir
purpos
studi
found
recombin
nucleocapsid
proteinbas
microtitr
plate
eia
elisar
tm
iggen
provid
high
degre
sensit
late
serum
sampl
specif
detect
antisarscov
igg
antibodi
human
serum
sampl
thu
elisar
tm
iggen
fulfil
criteria
screen
assay
largescal
studi
good
perform
elisar
tm
line
report
nucleocapsid
proteinbas
assay
shi
et
al
chang
et
al
guan
et
al
huang
et
al
liu
et
al
woo
et
al
b
indic
nucleocapsid
protein
promis
target
develop
serolog
assay
sarscov
infect
found
small
fraction
nonsar
sampl
falseposit
result
whether
due
crossreact
recent
infect
human
coronavirus
requir
studi
sampl
posit
elisar
tm
follow
confirmatori
assay
compar
ifa
elisar
tm
iggen
less
sensit
earli
sampl
eianeg
specimen
test
posit
ifa
howev
worth
note
one
ifaneg
specimen
show
high
od
read
test
elisar
tm
iggen
suggest
recombin
nucleocapsid
protein
use
elisar
tm
iggen
abl
detect
fraction
antisarscov
antibodi
reveal
ifa
antibodi
might
target
epitop
expos
acetonefix
sarscovinfect
vero
cell
use
ifa
sampl
high
ifa
titr
test
neg
elisar
tm
iggen
observ
line
hypothesi
recombin
nucleocapsid
proteinbas
assay
detect
differ
spectrum
antibodi
thu
sensit
may
increas
use
combin
assay
particular
appli
earli
stage
infect
major
sar
patient
develop
antibodi
nucleocapsid
protein
week
onset
fever
small
portion
antibodi
develop
within
first
week
hand
small
fraction
patient
never
develop
antibodi
understand
implic
differ
antibodi
respons
nucleocapsid
protein
import
develop
nucleocapsid
proteinor
sequencesbas
vaccin
progress
kim
et
al
zhu
et
al
attempt
made
investig
whether
elisar
tm
iggen
assay
appli
igm
antibodi
detect
earli
sampl
late
sampl
found
posit
antisarscov
igm
indic
recombin
nucleocapsid
protein
use
suboptim
antisarscov
igm
detect
anoth
clinic
applic
serolog
assay
confirm
infect
statu
suspect
case
import
current
avail
viral
rna
viru
isol
system
perfect
term
sensit
chen
et
al
regard
ifa
still
superior
provid
overal
higher
sensit
detect
antisarscov
antibodi
earlier
stage
howev
prepar
ifa
requir
handl
high
concentr
infecti
virus
high
contain
facil
requir
studi
develop
reliabl
igm
assay
urgent
need
improv
diagnost
accuraci
sarscov
infect
